Australian biotech market watch 05/02/10
Friday, 05 February, 2010
The Australian stock market has taken a dive in morning trading on the back of international concerns that the recovery will be slower than expected.
The All Ordinaries was down over 2.5% as of 11.30 this morning to 4523.1.
The health index has managed to keep its head above water, however, care of rises in two of the Big Three biotechs, CSL (ASX:CSL), up 19c to $31.31, and ResMed (ASX:RMD), up 6.3% to $6.37.
Other biotechnology stocks didn't fare as well. Living Cell Technology (ASX:LCT) continued its slide over the past couple of months by shedding 10% to 17.5c.
Mesoblast (ASX:MSB) also suffered a similar decline, down 19c to $1.65, which still puts it 9.2% up from one month ago, but shows that many of the gains made through January, when it topped $2.26 at one point, were transient.
Prima BioMed (ASX:PRR) also dropped by 1c to 13.5c, along with anti-leukaemia company, ChemGenex (ASX:CXS), which lost 7% of its value to 80c even.
Sirtex Medical (ASX:SRX) continued its shaky performance over the last couple of weeks, losing an additional 2.75% today, down to $6.04.
CathRx (ASX:CXD) did manage a gain, recovering some of its losses over the past two week of relatively heavy trading. Today it put on 2.5c to 39.5c.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
